RxSight RXST underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $59.12, a high estimate of $64.00, and a low estimate of $50.00. This upward trend is evident, with the current average reflecting a 21.0% increase from the previous average price target of $48.86.
Understanding Analyst Ratings: A Comprehensive Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive RxSight. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Saxon | Needham | Maintains | Buy | $64.00 | - |
| Thomas Stephan | Stifel | Raises | Buy | $64.00 | $54.00 |
| Robbie Marcus | JP Morgan | Raises | Overweight | $62.00 | $40.00 |
| Steven Lichtman | Oppenheimer | Raises | Outperform | $61.00 | $54.00 |
| David Saxon | Needham | Raises | Buy | $64.00 | $53.00 |
| Thomas Stephan | Stifel | Raises | Buy | $54.00 | $45.00 |
| Steven Lichtman | Oppenheimer | Raises | Outperform | $54.00 | $50.00 |
| Steven Lichtman | Oppenheimer | Raises | Outperform | $50.00 | $46.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to RxSight. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of RxSight compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for RxSight's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of RxSight's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on RxSight analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Financial Insights: RxSight
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, RxSight showcased positive performance, achieving a revenue growth rate of 77.65% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: RxSight's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -32.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): RxSight's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -5.7%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): RxSight's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.04%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: RxSight's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
